Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Core Insights - Inovio is currently awaiting the acceptance of its Biologics License Application (BLA) for INO-3107, which targets recurrent respiratory papillomatosis [2] - The company is developing a unique pipeline and in vivo protein production technology, which has the potential to significantly surpass the market opportunity presented by recurrent respiratory papillomatosis [2] Company Overview - Inovio's leadership includes Jacqueline Shea, PhD, serving as President and CEO, and Michael Sumner as Chief Medical Officer [2] - The company is positioned in the biotech sector, focusing on innovative treatments and technologies [2]